Skip to content

Prospective cohort study on diagnosis and treatment of Fabry disease

Prospective cohort study on diagnosis and treatment of Fabry disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086448
Enrollment
Unknown
Registered
2024-07-02
Start date
2024-07-10
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry disease

Interventions

Molecular chaperone therapy group:None

Sponsors

Zhongda Hospital Affiliated to Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 95 Years

Inclusion criteria

Inclusion criteria: A. The diagnosis of Fabry disease is clear; B. The data of peripheral blood specimen retention or genetic testing are detailed; C. Informed consent to this test and signed an informed consent form; D. Good compliance, and regular follow-up treatment according to doctor's advice.

Exclusion criteria

Exclusion criteria: A. People with cognitive dysfunction who can't communicate normally and other patients who can't cooperate with the investigation; B. Peripheral blood samples are missing or the genetic test data are not credible; C. Other circumstances that the researcher judges are not suitable for the group.

Design outcomes

Primary

MeasureTime frame
Urinary myeloid bodies;a-Gal A;Lyso-GL-3;

Secondary

MeasureTime frame
CMR;UCG;

Countries

China

Contacts

Public ContactZhang Xiaoliang

Department of Nephrology, Zhong Da Hospital Southeast University

tonyxlz@163.com+86 138 5229 0358

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026